Gerresheimer’s three existing production lines for RTF syringes (Ready-To-Fill syringes) at the Bunde plant (Germany) are now to be supplemented by an additional, latest-generation line. Gerresheimer is now
UBC and CDRD said that the transaction represents the first successful licensing agreement of a technology jointly developed between a UBC researcher and the full drug development platform
The transaction follows Abbott Laboratories global take over of Belgium-based Solvay‘s pharmaceutical business for EUR4.8bn in 2009. Solvay Pharma India has a presence in women’s health, gastroenterology, mental
Immunovaccine’s consolidated net loss was $1,499,000 in Q3 Fiscal 2010, compared to a net loss of $404,000 during the three month period ended September 30, 2009. Of this
Non-silicon electronics, light emitting diodes and pharmaceuticals are said to be the promising areas for bilateral cooperation, FOCUS News Agency reported. The agency quoted Chubais as saying that
Advaxis said that this initiation follows extensive review by the office of the Drugs Controller General of India, a blue ribbon commission of scientists convened to assess Advaxis
Pursuant to such agreement, Nostrum will in-license thrombolytics from IMTECH for clinical development and worldwide commercialisation. Nostrum president Nirmal Mulye said that the new thrombolytics are clot specific
Genzyme said that all fill/finish activities for Cerezyme (imiglucerase for injection), Myozyme (alglucosidase alfa), Fabrazyme (agalsidase beta) and Thyrogen (thyrotropin alfa for injection) for the US market now
The sales in the first nine months of 2010 were $1,216,019 compared to $911,543 in the corresponding previous year period. BioSyent incurred a loss of $31,987 in the
The decrease in net revenue was due to a planned reduction in sales to certain distributors with low gross profit margins, as the company made a shift in
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.